Athenex Inc (NASDAQ:ATNX) saw a large drop in short interest in the month of November. As of November 29th, there was short interest totalling 7,660,000 shares, a drop of 6.7% from the November 14th total of 8,210,000 shares. Based on an average daily trading volume, of 1,030,000 shares, the short-interest ratio is presently 7.4 days. Approximately 13.1% of the company’s stock are sold short.
Several equities research analysts have recently issued reports on ATNX shares. BidaskClub cut shares of Athenex from a “sell” rating to a “strong sell” rating in a research report on Thursday, October 10th. Royal Bank of Canada reaffirmed a “buy” rating and set a $31.00 price objective on shares of Athenex in a research report on Tuesday, November 19th. ValuEngine cut shares of Athenex from a “buy” rating to a “hold” rating in a research report on Wednesday, November 13th. Finally, SunTrust Banks started coverage on shares of Athenex in a research report on Friday, December 6th. They set a “buy” rating and a $28.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $24.75.
Athenex stock opened at $14.55 on Friday. The stock has a market cap of $1.34 billion, a P/E ratio of -10.10 and a beta of 0.02. The company has a fifty day simple moving average of $13.83 and a 200-day simple moving average of $15.16. Athenex has a 12-month low of $8.82 and a 12-month high of $21.11. The company has a current ratio of 2.37, a quick ratio of 2.06 and a debt-to-equity ratio of 0.45.
In other Athenex news, CEO Johnson Yiu Nam Lau purchased 6,000 shares of the firm’s stock in a transaction on Wednesday, October 16th. The stock was bought at an average price of $10.16 per share, with a total value of $60,960.00. Following the transaction, the chief executive officer now directly owns 3,055,959 shares of the company’s stock, valued at approximately $31,048,543.44. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Perceptive Advisors Llc purchased 30,000 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was acquired at an average cost of $13.58 per share, with a total value of $407,400.00. The disclosure for this purchase can be found here. Insiders acquired a total of 168,222 shares of company stock valued at $1,942,884 in the last three months. 18.80% of the stock is currently owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in the company. Perceptive Advisors LLC lifted its position in shares of Athenex by 92.7% during the 2nd quarter. Perceptive Advisors LLC now owns 9,822,118 shares of the company’s stock worth $187,636,000 after purchasing an additional 4,726,096 shares during the last quarter. BlackRock Inc. lifted its position in shares of Athenex by 26.0% during the 2nd quarter. BlackRock Inc. now owns 4,508,787 shares of the company’s stock worth $89,275,000 after purchasing an additional 930,726 shares during the last quarter. Orbimed Advisors LLC raised its stake in Athenex by 793.1% during the 2nd quarter. Orbimed Advisors LLC now owns 3,840,130 shares of the company’s stock worth $76,035,000 after acquiring an additional 3,410,130 shares in the last quarter. Vanguard Group Inc. raised its stake in Athenex by 33.9% during the 2nd quarter. Vanguard Group Inc. now owns 2,832,668 shares of the company’s stock worth $56,087,000 after acquiring an additional 717,109 shares in the last quarter. Finally, State Street Corp raised its stake in Athenex by 73.9% during the 3rd quarter. State Street Corp now owns 2,676,903 shares of the company’s stock worth $32,565,000 after acquiring an additional 1,137,517 shares in the last quarter. 55.83% of the stock is owned by institutional investors and hedge funds.
Athenex Company Profile
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.
See Also: What is the Book Value of a Share?
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.